Patents Assigned to Tularik Inc.
  • RIP: novel human protein involved in tumor necrosis factor signal transduction
    Patent number: 6211337
    Abstract: The invention relates to a human Receptor Interacting Protein (hRIP), nucleic acids which encode hRIP and methods of using the subject compositions; in particular, methods such as hRIP-based in vitro binding assays and phosphorylation assays for screening chemical libraries for lead compounds for pharmacological agents.
    Type: Grant
    Filed: August 11, 1998
    Date of Patent: April 3, 2001
    Assignee: Tularik Inc.
    Inventors: Vijay R. Baichwal, Jianing Huang, Hailing Hsu, David V. Goeddel
  • Arylsulfonanilide phosphates
    Patent number: 6211167
    Abstract: The invention provides compounds, compositions and methods relating to novel arylsulfonanilide derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular restenosis, infrections, atherosclerosis and hypercholesterolemia, or as lead compounds for the development of such agents.
    Type: Grant
    Filed: June 14, 2000
    Date of Patent: April 3, 2001
    Assignee: Tularik Inc.
    Inventor: Jonathan B. Houze
  • High-throughput screening assays for modulators of STAT4 and STAT6 activity
    Patent number: 6207391
    Abstract: This invention provides receptor peptides that have a high affinity for STAT4 and STAT6 polypeptides. Also provided are assays that are useful for identifying compounds that modulate the interaction between STAT4 and STAT6 polypeptides and their respective cellular promoters. The assays are amenable to high throughput screening.
    Type: Grant
    Filed: March 31, 1998
    Date of Patent: March 27, 2001
    Assignee: Tularik Inc.
    Inventors: Pengguang Wu, Judi McKinney
  • Pyrimidine derivatives
    Patent number: 6200977
    Abstract: Compounds and compositions are provided which are useful for the treatment of viral infections, particularly human Cytomegalovirus infection. The compounds include novel pyrimidine-based derivatives.
    Type: Grant
    Filed: February 12, 1999
    Date of Patent: March 13, 2001
    Assignee: Tularik Inc.
    Inventors: Timothy D. Cushing, Heather L. Mellon, Juan C. Jaen, John A. Flygare, Shi-Chang Miao, Xiaoqi Chen, Jay P. Powers
  • PPAR-&ggr; modulators
    Patent number: 6200995
    Abstract: Modulators of PPAR&ggr; activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.
    Type: Grant
    Filed: January 20, 1999
    Date of Patent: March 13, 2001
    Assignee: Tularik Inc.
    Inventors: Fabienne De la Brouse-Elwood, Jin-Long Chen, Timothy D. Cushing, John A. Flygare, Jonathan B. Houze, Juan C. Jaen, Lawrence R. McGee, Shi-Chang Miao, Steven Marc Rubenstein, Patrick C. Kearney
  • High-throughput screening assays for modulators of nucleic acid topoisomerases
    Patent number: 6197527
    Abstract: This invention provides novel assays for topoisomerase activity and for identifying topoisomerase inhibitors. The assays include both solid-phase and liquid-phase methods that are amenable to high throughput screening methods. The assays of the invention are readily adaptable to numerous types of topoisomerase, and are capable of identifying novel classes of topoisomerase activity modulators.
    Type: Grant
    Filed: July 13, 1999
    Date of Patent: March 6, 2001
    Assignee: Tularik Inc.
    Inventors: Anthony Simon Lynch, Binoj Joseph Matthew
  • Benzenesulfonamides and benzamides as therapeutic agents
    Patent number: 6191170
    Abstract: The invention provides compounds, compositions and methods relating to novel aromatic derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular restenosis, infections, atherosclerosis and hypercholesterolemia, or as lead compounds for the development of such agents.
    Type: Grant
    Filed: January 7, 1999
    Date of Patent: February 20, 2001
    Assignee: Tularik Inc.
    Inventor: Julio C. Medina
  • c-IAP1 and c-IAP2: inhibitors of apoptosis
    Patent number: 6187557
    Abstract: The invention provides methods and compositions relating to novel human cellular inhibitor of apoptosis proteins (c-IAP1/2) comprising a series of defined structural domain repeats and/or a RING finger domain; in particular, at least two of: a particular first domain repeat, a particular second domain repeat, and a particular third domain repeat, and/or a particular RING finger domain. The proteins provide a c-IAP specific function, with preferred proteins being capable of modulating the induction of apoptosis; for example, by binding a human tumor necrosis factor receptor associated factor (TRAF). The compositions include nucleic acids which encode the subject c-IAP and hybridization probes and primers capable of hybridizing with the disclosed c-IAP genes.
    Type: Grant
    Filed: December 8, 1995
    Date of Patent: February 13, 2001
    Assignee: Tularik Inc.
    Inventors: Mike Rothe, David V. Goeddel
  • IKAP proteins and methods
    Patent number: 6172195
    Abstract: The invention provides methods and compositions relating to IKAP proteins which regulate cellular signal transduction and transcriptional activation, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed IKAP encoding nucleic acids or purified from human cells. The invention provides isolated IKAP hybridization probes and primers capable of specifically hybridizing with the disclosed IKAP genes, IKAP-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: April 6, 1999
    Date of Patent: January 9, 2001
    Assignee: Tularik Inc.
    Inventors: Lucie Cohen, Patrick Baeuerle
  • Arylsulfonanilide derivatives
    Patent number: 6153585
    Abstract: The invention provides compounds, compositions and methods relating to novel arylsulfonanilide derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular restenosis, infections, atherosclerosis and hypercholesterolemia, or as lead compounds for the development of such agents.
    Type: Grant
    Filed: July 15, 1999
    Date of Patent: November 28, 2000
    Assignee: Tularik Inc.
    Inventors: Steven M. Rubenstein, Juan C. Jaen
  • High throughput screening assays for nucleic acid ligase modulators
    Patent number: 6153384
    Abstract: Screening assays for identifying ligase activity modulators are provided, in both solid phase and liquid phase formats. Solid phase formats detect ligase activity by ligating a labelled nucleic acid to a capture nucleic acid in the presence of the ligase modulator and detection of the labelled nucleic acid. Liquid phase assays detect ligation-dependent changes in interactive labels between nucleic acids such as proximity quenching of fluorescent labels. Compositions, apparatus and integrated systems for assays are also provided.
    Type: Grant
    Filed: February 19, 1998
    Date of Patent: November 28, 2000
    Assignee: Tularik Inc.
    Inventors: Anthony Simon Lynch, Ashok Ramesh Sanadi, Mohanram Sivaraja
  • Pentafluorobenzenesulfonamides and analogs
    Patent number: 6121304
    Abstract: The invention provides methods and compositions relating to novel pentafluorophenylsulfonamide derivatives and analogs and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly atherosclerosis and hypercholesterolernia, or as lead compounds for the development of such agents.
    Type: Grant
    Filed: January 6, 1999
    Date of Patent: September 19, 2000
    Assignee: Tularik Inc
    Inventors: John A. Flygare, Julio Cesar Medina, Bei Shan, David Louis Clark, Terry J. Rosen
  • SODD-specific antibodies and methods
    Patent number: 6110690
    Abstract: The invention provides methods and compositions relating to Suppressor of Death Domain (SODD) proteins which regulate cellular signal transduction and transcriptional activation, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed SODD encoding nucleic acids or purified from human cells. The invention provides isolated SODD hybridization probes and primers capable of specifically hybridizing with the disclosed SODD genes, SODD-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: August 29, 2000
    Assignee: Tularik Inc.
    Inventors: David V. Goeddel, Yingping Jiang
  • TRAF2-associated protein kinase and assays
    Patent number: 6107074
    Abstract: The invention provides methods and compositions relating to a novel human tumor necrosis factor receptor associated factor number two associated kinase protein. The invention provides hybridization probes and primers capable of hybridizing with the disclosed gene, nucleic acids encoding the kinase, methods of making the kinase proteins, and methods of using the compositions in diagnosis and drug screening.
    Type: Grant
    Filed: November 5, 1999
    Date of Patent: August 22, 2000
    Assignee: Tularik Inc.
    Inventors: Yeong Song, Mike Rothe
  • TRAF Inhibitors
    Patent number: 6063585
    Abstract: The invention concerns novel inhibitors of tumor necrosis factor receptor associated factor(TRAF) mediated signal transduction. The invention encompasses the novel inhibitor proteins (I-TRAFs), nucleic acid encoding them, methods for their recombinant production, and their use in screening assays and as pharmaceuticals.
    Type: Grant
    Filed: February 9, 1998
    Date of Patent: May 16, 2000
    Assignees: Genetech, Inc., Tularik, Inc.
    Inventors: David V. Goeddel, Mike Rothe
  • TRAF inhibitors
    Patent number: 6060303
    Abstract: The invention concerns novel inhibitors of tumor necrosis factor receptor associated factor-(TRAF) mediated signal transduction. The invention encompasses the novel inhibitor proteins (I-TRAFs), nucleic acid encoding them, methods for their recombinant production, and their use in screening assays and as pharmaceuticals.
    Type: Grant
    Filed: February 9, 1998
    Date of Patent: May 9, 2000
    Assignees: Genetech, Inc., Tularik, Inc.
    Inventors: David V. Goeddel, Mike Rothe
  • High-throughput screening assays for modulators of primase activity
    Patent number: 6043038
    Abstract: This invention provides novel assays for primase activity and for identifying modulators of primase activity. The assays include both solid-phase and liquid-phase methods that are amenable to high throughput screening methods. The assays of the invention are readily adaptable to numerous types of primase, and are capable of identifying novel classes of primase activity modulators.
    Type: Grant
    Filed: March 31, 1998
    Date of Patent: March 28, 2000
    Assignee: Tularik, Inc.
    Inventors: Mohanram Sivaraja, Ashok Sanadi, M. Gregory Peterson
  • CYP7 promoter-binding factors
    Patent number: 6027901
    Abstract: The invention provides methods and compositions relating to CPF proteins which regulate transcriptional activation, and related nucleic acids. The polypeptides may be produced recombinantly from transformed host cells from the disclosed CPF encoding nucleic acids or purified from human cells. The invention provides isolated CPF hybridization probes and primers capable of specifically hybridizing with the disclosed CPF genes, CPF-specific binding agents such as specific antibodies, and methods of making and using the subject compositions in diagnosis, therapy and in the biopharmaceutical industry.
    Type: Grant
    Filed: March 31, 1999
    Date of Patent: February 22, 2000
    Assignees: Tularik Inc., Sumitomo Pharmaceuticals Co., Ltd.
    Inventors: Bei Shan, Masahiro Nitta
  • Murine UCP3 polypeptides
    Patent number: 6025469
    Abstract: The invention provides methods and compositions relating to a novel family of UCP3 polypeptides and related nucleic acids involved in metabolic regulation. The polypeptides may be produced recombinantly from transformed host cells from the disclosed mUCP3 encoding nucleic acids or purified from mammalian cells. The invention provides isolated mUCP3 hybridization probes, knock-out/in constructs and primers capable of specifically hybridizing with the disclosed mUCP3 genes, mUCP3-specific binding agents such as specific antibodies, animals and cells modified with the subject mUCP3 nucleic acids, and methods of making and using the subject compositions in the biopharmaceutical industry.
    Type: Grant
    Filed: May 25, 1999
    Date of Patent: February 15, 2000
    Assignee: Tularik Inc.
    Inventors: Ning Zhang, M. Catherine Amaral, Jin-Long Chen
  • TRAF inhibitors
    Patent number: 6004553
    Abstract: The invention concerns novel inhibitors of tumor necrosis factor receptor associated factor-(TRAF) mediated signal transduction. The invention encompasses the novel inhibitor proteins (I-TRAFs), nucleic acid encoding them, methods for their recombinant production, and their use in screening assays and as pharmaceuticals.
    Type: Grant
    Filed: February 9, 1998
    Date of Patent: December 21, 1999
    Assignees: Genentech, Inc., Tularik, Inc.
    Inventors: David V. Goeddel, Mike Rothe